Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
ICI 182780 in Treating Women With Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 80
- Registration Number
- NCT00012025
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
- Conditions
- Recurrent Uterine Corpus CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 67
- Registration Number
- NCT00006903
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.